Molecular Biology Reports

, Volume 40, Issue 3, pp 2253–2261 | Cite as

Preeclampsia and ABO blood groups: a systematic review and meta-analysis

  • Patricia Nessralla Alpoim
  • Melina de Barros Pinheiro
  • Daniela Rezende Garcia Junqueira
  • Leticia Gonçalves Freitas
  • Maria das Graças Carvalho
  • Ana Paula Salles Moura Fernandes
  • Flávia Komatsuzaki
  • Karina Braga Gomes
  • Luci Maria Sant’Ana Dusse
Article

Abstract

Preeclampsia (PE) is a multifactorial pregnancy-specific syndrome which represents one of the leading causes of maternal mortality worldwide. Inherited thrombophilia have been investigated as risk factor for the development of PE and it is currently known that ABO blood group may impact haemostatic balance, having the non-O blood groups (A, B or AB) subjects increased risk for thrombus formation, as compared to those of group O. We performed a systematic review of the literature for published studies investigating whether ABO blood groups could influence PE developing. A sensitive search of four databases identified 45 unique titles. The retrieved papers were assessed independently by authors and a rigorous process of selection and data extract was conduct. Methodological quality of the included studies was also evaluated. Two studies met eligibility criteria. As a main finding of our systematic review, an association between the AB blood group and the occurrence of PE was detected based on two original studies. Considering the role of ABO blood groups on the hemostatic process and thrombus formation, special attention should be given to pregnant patients carrying the AB blood group in order to prevent the syndrome and improve prognosis.

Keywords

Preeclampsia ABO blood-group system Risk factors Systematic review 

Notes

Acknowledgments

This work received grants from MCT/CT-Saúde and Decit/SCTIE/MS through the National Counsel of Technological, CNPq and FAPEMIG. APSMF, DRGJ, MGC and LMSD are grateful to the National Counsel of Technological and Scientific Development of Brazil (CNPq) for received research fellowship.

Conflict of interest

All authors disclose no financial or personal relationship with other people or organizations that could inappropriately influence their work.

References

  1. 1.
    Young BC, Levine RJ, Karumanchi SA (2010) Pathogenesis of preeclampsia. Annu Rev Pathol 5:173–192PubMedCrossRefGoogle Scholar
  2. 2.
    ACOG Practice Bulletin (2002) Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 77(1):67–75Google Scholar
  3. 3.
    Higgins JR, Walshe JJ, Darling MR, Norris L, Bonnar J (1998) Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 179(2):520–526PubMedCrossRefGoogle Scholar
  4. 4.
    Tharmaratnam S (2000) Fetal distress. Baillieres Best Pract Res Clin Obstet Gynaecol 14(1):155–172PubMedCrossRefGoogle Scholar
  5. 5.
    Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br Med J 330(7491):565CrossRefGoogle Scholar
  6. 6.
    Agorastos T, Karavida A, Lambropoulos A, Constantinidis T, Tzitzimikas S, Chrisafi S, Saravelos H, Vavilis D, Kotsis A, Bontis J (2002) Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. J Matern Fetal Neonatal 12(4):267–273CrossRefGoogle Scholar
  7. 7.
    Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB (2000) Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 96(1):45–49PubMedCrossRefGoogle Scholar
  8. 8.
    De Groot CJ, Bloemenkamp KW, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der Meer F, De Ronde H, Oei SG, Kanhai HH, Rosendaal FR (1999) Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 181(4):975–980PubMedCrossRefGoogle Scholar
  9. 9.
    D’Aniello G, Florio P, Sabatini L, Severi FM, Fineschi D, Cito G, Guidoni CG, Petraglia F (2003) The search for thrombophilic gene mutations in women with gestational hypertension does not help in predicting poor pregnancy outcome. J Hypertens 21(10):1915–1920PubMedCrossRefGoogle Scholar
  10. 10.
    Fabbro D, D’Elia AV, Spizzo R, Driul L, Barillari G, Di Loreto C, Marchesoni D, Damante G (2003) Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest 56(1):17–22PubMedCrossRefGoogle Scholar
  11. 11.
    De Maat MP, Jansen MW, Hille ET, Vos HL, Bloemenkamp KW, Buitendijk S, Helmerhorst FM, Wladimiroff JW, Bertina RM, De Groot CJ (2004) Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2(9):1588–1593PubMedCrossRefGoogle Scholar
  12. 12.
    Dusse LM, Carvalho MG, Braganca WF, Paiva SG, Godoi LC, Guimaraes DA, Fernandes AP (2007) Inherited thrombophilias and pre-eclampsia in Brazilian women. Eur J Obstet Gynecol Reprod Biol 134(1):20–23PubMedCrossRefGoogle Scholar
  13. 13.
    Lin J, August P (2005) Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 105(1):182–192PubMedCrossRefGoogle Scholar
  14. 14.
    do Prado AD, Piovesan DM, Staub HL, Horta BL (2010) Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol 116(6):1433–1443PubMedCrossRefGoogle Scholar
  15. 15.
    Abou-Nassar K, Carrier M, Ramsay T, Rodger MA (2011) The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 128(1):77–85PubMedCrossRefGoogle Scholar
  16. 16.
    Morelli VM, de Visser MC, van Tilburg NH, Vos HL, Eikenboom JC, Rosendaal FR, Bertina RM (2007) ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 97(4):534–541PubMedGoogle Scholar
  17. 17.
    Tirado I, Mateo J, Soria JM, Oliver A, Martinez-Sanchez E, Vallve C, Borrell M, Urrutia T, Fontcuberta J (2005) The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 93(3):468–474PubMedGoogle Scholar
  18. 18.
    Paiva SG, Carvalho MG, Ribeiro DD, Gomes KB, Santos MS, Oliveira MS, Lages GG, Dusse LM, Fernandes AP (2009) Polymorphisms in exons 6 and 7 of the ABO locus and their association with venous thrombosis in young Brazilian patients. Blood Coagul Fibrinol 20(2):122–128CrossRefGoogle Scholar
  19. 19.
    Guimarães DA, dos Santos MS, Gomes KB, van der Bom JG, Rios DR, Cardoso J, Franco RM, Teixeira GS, Dusse LM, Carvalho M, Fernandes AP (2012) Interaction between oral estrogen plus progestogen therapy and ABO blood groups on coagulation activation in postmenopausal women. Menopause 19(3):339–345PubMedCrossRefGoogle Scholar
  20. 20.
    Pike LA, Dickins AM (1954) ABO blood groups and toxaemia of pregnancy. Br Med J 2(4883):321–323PubMedCrossRefGoogle Scholar
  21. 21.
    Pregnancy WGoHBPi (2000) Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 183:S1–S22Google Scholar
  22. 22.
    Wells GA, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2010) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa, OttawaGoogle Scholar
  23. 23.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 18(6):800–804CrossRefGoogle Scholar
  24. 24.
    Sanderson S, Tatt ID, Higgins JP (2007) Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 36(3):666–676PubMedCrossRefGoogle Scholar
  25. 25.
    Higgins JPT GS (ed) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]Google Scholar
  26. 26.
    Spinillo A, Capuzzo E, Baltaro F, Piazzi G, Iasci A (1995) Case-control study of maternal blood group and severe pre-eclampsia. J Hum Hypertens 9(8):623–625PubMedGoogle Scholar
  27. 27.
    Hiltunen LM, Laivuori H, Rautanen A, Kaaja R, Kere J, Krusius T, Paunio M, Rasi V (2009) Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population-based nested case-control study. Thromb Res 124(2):167–173PubMedCrossRefGoogle Scholar
  28. 28.
    Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345(8943):152–155PubMedCrossRefGoogle Scholar
  29. 29.
    Ruggeri ZM (2003) Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1(7):1335–1342PubMedCrossRefGoogle Scholar
  30. 30.
    Kamphuisen PW, Eikenboom JC, Bertina RM (2001) Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 21(5):731–738PubMedCrossRefGoogle Scholar
  31. 31.
    Bowen DJ (2003) An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 1(1):33–40PubMedCrossRefGoogle Scholar
  32. 32.
    Mannucci PM, Capoferri C, Canciani MT (2004) Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 126(2):213–218PubMedCrossRefGoogle Scholar
  33. 33.
    Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69(6):1691–1695PubMedGoogle Scholar
  34. 34.
    Sousa NC, Anicchino-Bizzacchi JM, Locatelli MF, Castro V, Barjas-Castro ML (2007) The relationship between ABO groups and subgroups, factor VIII and von Willebrand factor. Haematologica 92(2):236–239PubMedCrossRefGoogle Scholar
  35. 35.
    Thornton CA, Bonnar J (1977) Factor VIII-related antigen and factor VIII coagulant activity in normal and pre-eclamptic pregnancy. Br J Obstet Gynaecol 84(12):919–923PubMedCrossRefGoogle Scholar
  36. 36.
    Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM (2003) Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 88(9):1029–1034PubMedGoogle Scholar
  37. 37.
    Hulstein JJ, van Runnard Heimel PJ, Franx A, Lenting PJ, Bruinse HW, Silence K, de Groot PG, Fijnheer R (2006) Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost 4(12):2569–2575PubMedCrossRefGoogle Scholar
  38. 38.
    Alpoim PN, Gomes KB, Godoi LC, Rios DR, Carvalho MG, Fernandes AP, Dusse LM (2011) ADAMTS13, FVIII, von Willebrand factor, ABO blood group assessment in preeclampsia. Clin Chim Acta 412(23–24):2162–2166PubMedCrossRefGoogle Scholar
  39. 39.
    Molvarec A, Rigo J Jr, Boze T, Derzsy Z, Cervenak L, Mako V, Gombos T, Udvardy ML, Harsfalvi J, Prohaszka Z (2009) Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 101(2):305–311PubMedGoogle Scholar
  40. 40.
    Clark P, Wu O (2008) ABO(H) blood groups and pre-eclampsia. A systematic review and meta-analysis. Thromb Haemost 100(3):469–474PubMedGoogle Scholar
  41. 41.
    Amin N, Tahir S, Abadi N (1989) Association of blood groups with preeclamptic toxemia. Med Sci Res 17:861Google Scholar
  42. 42.
    May D (1973) Letter: maternal blood group A and pre-eclampsia. Br Med J 4(5894):738PubMedCrossRefGoogle Scholar
  43. 43.
    Lawoyin TO, Ani F (1996) Epidemiologic aspects of pre-eclampsia in Saudi Arabia. East Afr Med J 73(6):404–406PubMedGoogle Scholar
  44. 44.
    Witsenburg CP, Rosendaal FR, Middeldorp JM, Van der Meer FJ, Scherjon SA (2005) Factor VIII levels and the risk of pre-eclampsia, HELLP syndrome, pregnancy related hypertension and severe intrauterine growth retardation. Thromb Res 115(5):387–392PubMedCrossRefGoogle Scholar
  45. 45.
    Clark P, O’Sullivan A, Forgan M et al (2005) ABO and secretor genotypes and the risk of pre-eclampsia. J Thromb Haemost 3(Suppl 1):P0493Google Scholar
  46. 46.
    Clark P, Walker ID, Govan L, Wu O, Greer IA (2008) The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol 140(2):236–240PubMedGoogle Scholar
  47. 47.
    Than NG, Romero R, Goodman M, Weckle A, Xing J et al (2009) A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci USA 106:9731–9736PubMedCrossRefGoogle Scholar
  48. 48.
    Than NG, Abdul RO, Magenheim R, Nagy B, Fule T et al (2008) Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Virchows Arch 453:387–400PubMedCrossRefGoogle Scholar
  49. 49.
    Kliman HJ, Sammar M, Lynch S, Grimpel Y, Pick E et al (2008) PP13 (galectin-13) mediated zones of necrosis diverts the maternal immune response away from the decidual spiral arterioles. Hypertens Pregnancy 27:578Google Scholar
  50. 50.
    Meiri H, Huppertz B, Cetin I (2011) Development of early non-invasive markers and means for the diagnosis and progression monitoring of preeclampsia and tailoring putative therapies (project pregenesys 037244). Placenta 32(Suppl):S1–S3PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Patricia Nessralla Alpoim
    • 1
  • Melina de Barros Pinheiro
    • 1
  • Daniela Rezende Garcia Junqueira
    • 1
    • 2
  • Leticia Gonçalves Freitas
    • 1
  • Maria das Graças Carvalho
    • 1
  • Ana Paula Salles Moura Fernandes
    • 1
  • Flávia Komatsuzaki
    • 1
  • Karina Braga Gomes
    • 1
  • Luci Maria Sant’Ana Dusse
    • 1
  1. 1.Department of Clinical and Toxicological Analyses, School of PharmacyFederal University of Minas GeraisBelo HorizonteBrazil
  2. 2.Centre of Drug Studies (Cemed), Department of Social Pharmacy, School of PharmacyFederal University of Minas GeraisBelo HorizonteBrazil

Personalised recommendations